<DOC>
	<DOCNO>NCT00882258</DOCNO>
	<brief_summary>Two ( 2 ) dose level Proellex placebo administer once-daily 91 day . Following screen pre-treatment endometrial biopsy , subject follow monthly three month treatment phase .</brief_summary>
	<brief_title>Study Proellex Pre-menopausal Women With Symptomatic Uterine Fibroids</brief_title>
	<detailed_description>Two ( 2 ) dose level Proellex placebo administer once-daily 91 day . Following screen pre-treatment endometrial biopsy , subject follow monthly three month treatment phase . At three-month treatment visit , subject enter open-label extension treatment protocol , deem eligible . At four month first treatment visit , subject elect enter open-label study assess final follow-up visit .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>At least one leiomyoma must identifiable measurable abdominal/pelvic ultrasound . Must history one following leiomyomataassociated symptom , excessive menstrual bleeding , pain Postmenopausal woman , define one following : 1. six month ( immediately prior Screening visit ) without menstrual period , 2. prior hysterectomy and/or oophorectomy Subjects document endometriosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Uterine fibroid</keyword>
</DOC>